4Q06 Hepsera sales: $66M, +29% year-over-year and +20% quarter-over-quarter. <A HREF="http://biz.yahoo.com/bw/070131/20070131006128.html?.v=1" target="_blank">http://biz.yahoo.com/bw/070131/20070131006128.html?.v=1</A> IDIX has gotta be lowballing with the $20M annual guidance for Tyzeka/Sebivo.